CN1111171C - Heparin and its preparing process - Google Patents
Heparin and its preparing process Download PDFInfo
- Publication number
- CN1111171C CN1111171C CN00125093A CN00125093A CN1111171C CN 1111171 C CN1111171 C CN 1111171C CN 00125093 A CN00125093 A CN 00125093A CN 00125093 A CN00125093 A CN 00125093A CN 1111171 C CN1111171 C CN 1111171C
- Authority
- CN
- China
- Prior art keywords
- heparin
- ethanol
- filtering
- resin
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a heparin and a preparing process thereof. An extraction initial raw material of the heparin is the intestinal mucosa, and a heparin solution is obtained by enzyme hydrolysis or salt hydrolysis. A heparin mucopolysaccharide substance is adsorbed, washed and eluted by polystyrene divinylbenzene trimethylamine quaternary amine type strong basic anion exchange resin. The present invention is characterized in that the substance is refined and purified to finally obtain the fine heparin; other heparinmucopolysaccharide is separated from the heparin by the fractional precipitation of an organic solvent, comprising dermatan sulfate substances, etc. The quality of the final fine heparin reaches high unit titer, sterility, no pyrogen and no impurities by the refining operation of secondary hydrogen peroxide oxidation. A light transmittance rate and yield all reach international and domestic leading level. The heparin has simple and convenient operation and is suitable for mass production.
Description
The invention discloses heparin and a preparation method thereof, belonging to a preparation method of biological medicines.
Heparin is a natural anticoagulant, and its sodium salt is called heparin sodium and calcium salt is called heparin calcium. The 10mg heparin can inhibit 500ml plasma coagulation within 4 hours, and is widely used for preventing thrombosis and embolism before and after various surgical operations, preventing blood coagulation during blood transfusion and storing fresh blood as anticoagulant, and preventing and treating hyperlipidemia and atherosclerosis in small dosage. Heparin is widely known to be distributed in mammalian tissues such as intestinal mucosa, duodenum, lung, liver, pancreas, placenta, and blood. Heparin, like most glycosaminoglycans, exists in vivo as a protein-bound complex. This complex has anticoagulant activity and increases in activity as the protein is removed. The traditional production process of heparin sodium has the defects of extraction from bovine lung, low yield, complex process and incapability of meeting the quality requirement of the final product. In addition, the extraction from intestinal mucosa includes the extraction process of Cetyl Trimethyl Ammonium Bromide (CTAB) and the extraction of ether with separating funnel, and the process is complicated, has low yield and is not suitable for industrial production.
The invention aims to disclose heparin and a preparation method thereof, which have the advantages of simplifying production procedures, improving product quality and improving industrial production capacity.
The invention is realized in such a way that in the extraction section, the heparin is noted to be relatively stable in an alkaline medium, and the alkali can break the combination of the heparin and the protein, so that the extractionof the heparin in the tissues adopts alkaline hot water or boiling water leaching of sodium salt. Within such extracts, soluble heparin-protein complexes remain. The invention has two methods for decomposing heparin-protein in crude heparin (1) adding protein hydrolase during extraction, wherein the enzyme is bacterial protease, trypsinase, pancreatin, pepsin and cucurbit proteolytic enzyme, 2) salt decomposition technique, wherein the salt decomposition is usually combined with heat denaturation and coagulant (alum, aluminum sulfate) denaturation to remove protein. The product obtained by the above method still contains other mucopolysaccharides, nucleic acid and non-removed mucopolysaccharidesA protein. The invention adopts anion exchanger or long-chain quaternary ammonium salt to carry out fractional separation, and then the fractional precipitation and H precipitation are carried out by organic solvent2O2And (5) carrying out secondary oxidation to obtain refined heparin.
First, enzymolysis resin method
1. Process route
2. Process (carried out in the following order)
(1) Enzymolyzing fresh intestinal mucosa (total solid content is 5-7%), stirring, adding minced pancreas 5-10kg (about 0.5-1kg of pancreatin powder), adjusting pH to 8.5-9.0 with 30-40% sodium hydroxide, heating to 40-50 deg.C, and maintaining for 2-3 hr to maintain pH at 8.5-9.0.
Adding 50 kg of crude salt, heating to about 90 ℃, adjusting the pH value to about 6.5 by using 6N hydrochloric acid, stopping stirring, preserving the temperature for 20 minutes, and filtering by using a cloth bag.
(2) Ion exchange adsorption, cooling the filtrate to below 50 deg.C, adjusting pH to 7.0 with 6N sodium hydroxide, adding 50 kg D-254 strong base anion exchange resin, stirring for about 5 hr, and removing the liquid after the exchange.
(3) Washing and eluting, and rinsing the resin with tap water until the resin is clear. The resin was washed with 2M sodium chloride (equivalent to about the volume of the resin) for 15 minutes under agitation, the washing solution was discarded, and the resin was washed 2 times with 1.2M sodium chloride (about twice the volume of the resin) in the same manner.
Eluting with 3-5M sodium chloride (about half of the volume of the resin) for 1 hr, collecting the eluate, and eluting with 3M sodium chloride (about one third of the volume of the resin) for 2 times. The eluates were combined.
(4) Ethanol precipitation: the eluent is filtered once with paper pulp to clarify. Adding 95% ethanol in an amount which is 0.9 times the volume of the mixture, and precipitating for 8-12 hours in a cold place. Siphoning the supernatant to remove, draining, or suspending in a cloth bag to drain, washing with 95% ethanol for 2-3 times, draining, and vacuum drying at 60-80 deg.C to obtain heparin crude product.
(5) Acidifying: adding pure water and chloride according to the ratio of the crude product, water and sodium chloride of 7: 100: 1, putting the crude product into a reaction pot, stirring to completely dissolve the crude product, simultaneously cooling the reaction pot to 10 ℃, adjusting the pH value of the liquid to 1.9 by using 6NHCL, and adjusting the pH value of the filtrate to 9.0-11.0 by using a plate-and-frame filter pressing (diatomite-assisted filtration).
(6) First oxidation: keeping the clear liquid at a constant temperature of 25 deg.C, slowly adding 2% hydrogen peroxide, maintaining pH at 9-11 for 24 hr, filtering with 0.2 μm microporous membrane, precipitating with 0.8 times of 95% ethanol overnight (5-10 deg.C).
(7) And (3) second oxidation: siphoning supernatant waste ethanol, adding precipitate into 1% sodium chloride solution with 10 times of crude product weight, dissolving completely, cooling to below 10 deg.C, filtering with 0.2 μm microporous membrane, heating to 25 deg.C, adjusting pH with 5N sodium hydrochloride 9-11, adding 0.5-1.5% H2O2After preserving heat for 24 hours, filtering the mixture by a 0.2 mu m microporous membrane, adjusting the pH to 4.0-7.00, adding 0.7 times of 95% ethanol into the clear solution for precipitation, and standing the mixture overnight.
(8) Absorbing the alcohol supernatant of heparin after 6 hours, dissolving the crude product in 1% pyrogen-free sodium chloride solution 6-10 times the weight of the crude product, cooling to below 10 ℃, filtering the solution again by using a 0.2 mu m microporous membrane, precipitating the solution by adding 95% ethanol 0.65-0.7 times (volume, the same below) the volume of the solution, and standing overnight.
(9) Siphoning the waste ethanol the next day, filtering the precipitate to dryness, or suspending and filtering to dryness, and washing with 95% ethanol for 2-3 times.
(10) The finished product enters a vacuum drying oven at the temperature of 60-80 ℃, is dried for 24-36 hours and then is ball-milled, and the refined heparin 170 and 180iu/mg are obtained after crushing, and the light transmittance reaches the standard of British pharmacopoeia PB98 edition.
Second, salt decomposition of resin
1. Process route
2. The process (in the following order):
1) extraction: adding edible salt into 1000 kg of fresh intestinal mucosa according to 3.3%, adjusting pH to 8.8-9.0 with sodium hydroxide, gradually heating to 50-55 deg.C, maintaining the temperature for 2 hr, continuously heating to 95 deg.C for 10 min, cooling to below 60 deg.C, filtering with 30 mesh double-layer cloth, and collecting filtrate.
2) Adsorption: adding the D-254 resin into the mixture according to the proportion of 3-5% (by weight), stirring, adsorbing for 6 hours, stopping stirring, removing the waste liquid, and collecting the resin. Rinse the resin with tap water until clean.
3) And (2) washing and eluting, pouring the rinsed resin into a cylinder, stirring and washing for 1 hour by using 1.5 times of the volume of the resin with 1.3N sodium chloride solution, washing once with 1.4N sodium chloride solution after draining, stirring and washing for 2 times with 3N sodium chloride for the first time, 5 hours for the second time, 1.5 times of the resin for the first time and 1 time of the resin for the second time, and collecting the eluent.
4) Precipitating with ethanol, mixing the filtrates, filtering with paper pulp, filtering to obtain clear filtrate, adding 1 volume (V/V) of 95% ethanol, precipitating overnight, siphoning to remove supernatant, vacuum filtering or drying with cloth bag, washing with 95% ethanol for 2-3 times, and drying at 60-80 deg.C in vacuum drying oven to obtain heparin crude product. The next procedure is operated according to 5-10 methods of an enzymolysis process.
The invention can be used for industrial production, and the heparin product obtained by using a secondary hydrogen peroxide oxidation technology after removing acid foreign protein after acidification is tested by a XXXXXX medicine: the unit titer of the product is always kept above 170 international units per milligram, while the Chinese pharmacopoeia, European pharmacopoeia and the like all express above 150 international units per milligram. The solubility, clarity and absorption in ultraviolet light of the refined heparin all reach the technical indexes of domestic and foreign high-grade products; the OD value is specified to be less than 0.20 at the wavelength of 280nm, the OD value is specified to be less than 0.15 at the wavelength of 260nm and is 0.060-0.080 for the product of the invention, and is less than or equal to 0.018 at the wavelength of 0.040-0.050 at the wavelength of 400 nm; 420nm is less than or equal to 0.015; 470nm is less than or equal to 0.010 nm, and the product is completely sterile and pyrogen-free (without external interference) in the operation process of the invention. In particular, in recent years, foreign manufacturers have required the dermatan sulfate content in products to be less than 3%, whereas heparin produced by the present invention has a dermatan sulfate content of only about 0.5%.
Example 1:
firstly, a crude working section:
adding 2500 kg of fresh intestinal mucosa into a reaction pot, adding 12.5 kg of porcine pancreatin powder while stirring, adjusting pH to 8.0-8.5 with 30-40% sodium hydroxide, heating to 45 deg.C, and maintaining the temperature for 2-3 hr. Adding 125 kg of salt, heating to 90 ℃, adjusting pH to 6.5 +/-by using 6N hydrochloric acid, stopping stirring, keeping the temperature for 20 minutes, filtering by using a cloth bag to obtain about 3000 liters of clear liquid, adjusting pH to 7.0 by using 6N sodium hydroxide, stirring LK TY120 kg of D-254 resin, adsorbing for 5 hours, removing liquid, collecting the adsorbed resin, rinsing by using tap water, stirring and washing the resin by using 2M sodium chloride for 15 minutes, and washing by using 1.2M sodium chloride for 2 times. Eluting with 5M sodium chloride 65 under stirring for 1 hr, collecting eluate, eluting with 5M sodium chloride 40 under stirring for half an hour, collecting filtrate and eluting under stirring for 1 hr, collecting eluate, and washing with 1.2M sodium chloride for 2 times. Eluting with 65L 5M sodium chloride under stirring for 1 hr, collecting eluate, eluting with 40L 5M sodium chloride for half an hour, mixing the filtrate with the first solution to obtain 100L, cleaning with Buchner funnel, precipitating with 90L 95% ethanol overnight, siphoning the supernatant with waste ethanol the next day, filtering the precipitate, washing with 95% ethanol for 1-2 times, and drying in vacuum drying oven at 60-80 deg.C for 24 hr to obtain 1050 g crude heparin product with titer of 102 unit per mg. The total titer was 1.07 hundred million units.
Second, refining section
1050 g of the crude product is added with 12L of 1% sodium chloride solution, stirred to be fully dissolved, then the pH value is adjusted to 1.9 by 6N hydrochloric acid, 11.5L of clear liquid is collected by plate-and-frame filter pressing, 230ml of hydrogen peroxide is added after the pH value is adjusted to 9.0-11.0, the solution is kept warm for 24 hours at 25 ℃ and then is filtered by 0.8 times of 95% ethanol for precipitation for 6 hours, waste filtration is carried out, 10L of pyrogen-free water (containing 1% sodium oxide) is added into the precipitate for dissolution, then the solution is filtered by a 0.2μm microporous membrane, the pH value is adjusted to 9-11, after the solution is heated to 25 ℃, 115 ml of hydrogen peroxide is added for keeping warm for 24 hours, 0.65 times of 95% ethanol precipitation is carried out by the 0.2μm microporous membrane, after the precipitate is dissolved for the second time and is filtered by the 0.2μm microporous membrane, 0.7 times of 95% ethanol precipitation is carried out, the precipitate is kept stand overnight, the precipitate is filtered and dried by the next day, the precipitate is washed by, obtaining 581 g of refined heparin, measuring the potency 173 iu/mg, and the total potency is 1.005 hundred million u.
Example 2
First, rough working section
2500 kg of fresh intestinal mucosa is added with 82.5 kg of edible salt, the pH value is adjusted to 8.8-9.0 by sodium hydroxide, and the temperature is gradually increased to 50-55 ℃ and kept for 2 hours. The temperature is increased to 95 ℃ continuously for 10 minutes, the temperature is cooled to below 60 ℃, and about 2600ml of filtrate is collected by filtering with a double-layer gauze. Then adding 125 kg of D-254 resin, stirring and adsorbing for 6 hours, stopping stirring, removing waste liquid, collecting the resin, and rinsing with water; adding 190 liters of 1.3N sodium chloride solution, stirring and washing for 1 hour; filtering to dryness, stirring and washing with 190 liters of 1.4N sodium chloride solution, stirring and washing for 1 hour, filtering to dryness resin, adding 190 liters of 3N sodium chloride, stirring and eluting for 5 hours, collecting filtrate, adding 120 liters of 3N sodium chloride into the resin, stirring for 2 hours, merging the 2 times of filtrate, adding 310 liters of 95% ethanol, stirring for 10 minutes, and standing overnight; siphoning supernatant waste ethanol the next day, washing precipitate with 95% ethanol for 1-2 times after being filtered, and drying in a vacuum drying oven at 60-80 ℃ for 24 hours to obtain 938 g crude product with unit titer of 105 units/mg and total titer of 0.985 hundred million units.
Second, refining section
The operation of the refining section was the same as that of example (1), and after pulverization, 529 g of refined heparin was obtained, and the titer was measured to be 176iu/mg, and the total titer was 0.931 additional unit.
The invention simplifies the traditional production technology, the heparin obtained by the invention has high unit titer, is sterile, pyrogen-free, impurity-free, simple to operate, suitable for industrial production and reaches the international and domestic advanced level, and the heparin quality is a novel technology for producing heparin.
Claims (5)
1. A method for preparing heparin comprises extracting heparin from bovine lung; extracting liver and thymus of mammal and intestinal mucosa of cow, sheep and pig, hydrolyzing with enzyme or salt, separating with strong basic anion exchange resin to obtain heparin crude product, and performing enzymolysis to obtain heparin crude product according to the following steps:
adding pancreatin and sodium chloride into the intestinal mucosa under the condition of pH8.5-9.0, heating to 40-50 ℃, keeping the temperature for 2-3 hours, heating to 90 ℃, adjusting the pH to 6.5 by using 6N sodium hydroxide, filtering by using a cloth bag to obtain clear liquid, adding 3-5% (by weight) of D254 resin, stirring and adsorbing for 5 hours, washing the resin, precipitating the eluted crude liquid containing heparin by using 95% ethanol with the volume of 1: 0.9 times, and drying in vacuum to obtain crude heparin; the salt hydrolysis for producing the heparin crude product is carried out according to the following sequence process flows: adding 3.3 percent (by weight) of edible salt and sodium hydroxide into intestinal mucosa, adjusting the pH value to 8.8-9.0, gradually heating to 50-55 ℃, preserving the heat for 2 hours, continuously heating to 95 ℃, maintaining the temperature for 10 minutes, cooling to 60 ℃, filtering with 30-mesh double-layer gauze, collecting filtrate, adding 3-5 percent (by weight) of D254 resin, stirring and adsorbing for 6 hours, discarding waste liquid, rinsing the resin with water, washing and eluting to obtain heparin-containing liquid, adding 1 time (by volume) of 95 percent ethanol, precipitating overnight, siphoning supernatant, carrying out suction filtration or suspension filtration, washing with 95 percent ethanol for 2-3 times, drying in a vacuum drying oven at 60-80 ℃ to obtain a heparin crude product, and refining and purifying the heparin crude product, and is characterized in that:
the refining purification is carried out by secondary hydrogen peroxide oxidation and fractional precipitation of organic solvent, and the refining process flow comprises the following steps: dissolving the crude product in 10-15 times (volume) 1% saline, adding 6N hydrochloric acid to adjust pH to 1.0-2.0 to acidify heparin, filtering at 5-10 deg.C to obtain clear solution, adjusting pH to 9.0-11.0, and adding 0.5-1.5% H2O2Heating to 25 deg.C and holding for 24 hr, filtering with 0.2 μm microporous membrane, precipitating with 0.8 times (volume) of 95% ethanol for 6 hr, siphoning out supernatant, dissolving precipitate with 1% sodium chloride solution, adjusting pH to 9.0-11.0, and adding 1.5% H2O2Heating to 25 deg.C and keeping the temperature for 24 hoursFiltering with 0.2 μm microporous membrane, precipitating with 0.7 volume times of 95% ethanol for 6 hr, siphoning out supernatant, dissolving the precipitate in 1% pyrogen-free sodium chloride solution 6-10 times of the crude product weight, cooling to below 10 deg.C, filtering with 0.2 μm microporous membrane to clarify the liquid, adding0.65-0.7 volume times of 95% ethanol into the supernatant, standing overnight, sucking out supernatant the next day, filtering to dry, washing with 95% ethanol for 1-2 times, vacuum drying at 60-80 deg.C for 24-36 hr, and ball milling to obtain refined heparin.
2. The heparin preparation method according to claim 1, wherein said heparin is acidified and adjusted to pH1.9 with 6N hydrochloric acid to remove a large amount of acidic proteins.
3. The heparin preparation method according to claim 1, wherein the secondary oxidation of heparin is performed by hydrogen peroxide method, and the amount of alcohol added in the third time is 0.65 times (volume).
4. The heparin preparation method according to claim 1, wherein the enzymes used in the enzymolysis handicraft of crude heparin comprise pancreatin, pancreas, protease and heparin-specific enzyme, and the quality of the crude heparin is controlled between 80u/mg and 100 u/mg.
5. Heparin obtainable by the process for the preparation of heparin according to the preceding claim, characterized in that the unit titer is between 160 and 180 iu/mg; the detected amount of dermatan sulfate is less than or equal to 0.5 percent, and the light transmittance of the finished product solution is less than or equal to 0.08 at the wavelength of 280 nm; the wavelength is less than or equal to 0.06 at the wavelength of 260 nm; the wavelength at 400nm is less than or equal to 0.018; the wavelength is less than or equal to 0.015 at the position of 420 mm; the wavelength is less than or equal to 0.010 at 470nm, and the product is sterile and pyrogen-free.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00125093A CN1111171C (en) | 2000-09-07 | 2000-09-07 | Heparin and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00125093A CN1111171C (en) | 2000-09-07 | 2000-09-07 | Heparin and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1283636A CN1283636A (en) | 2001-02-14 |
| CN1111171C true CN1111171C (en) | 2003-06-11 |
Family
ID=4590892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00125093A Expired - Fee Related CN1111171C (en) | 2000-09-07 | 2000-09-07 | Heparin and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1111171C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100344769C (en) * | 2005-08-04 | 2007-10-24 | 清华大学 | Production of low-molecular heparin |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300324C (en) * | 2003-12-12 | 2007-02-14 | 长春工业大学 | Method for extraction and purification of polysaccharide from pilose antler |
| CN100425624C (en) * | 2006-05-11 | 2008-10-15 | 中国农业大学 | Method for simultaneous extraction of sodium heparin and antibacterial peptide of pig intestinal mucosa |
| CN100439402C (en) * | 2006-10-12 | 2008-12-03 | 孙红 | Method for extracting heparin using lecithin liquid membrane separating method |
| CN102643369A (en) * | 2011-03-21 | 2012-08-22 | 如皋市坝新肠衣有限公司 | Resin separation and purification process of heparin sodium |
| CN102993335A (en) * | 2011-09-09 | 2013-03-27 | 谭科 | Heparin sodium balance extraction method |
| CN105504096A (en) * | 2012-12-08 | 2016-04-20 | 青岛九龙生物医药有限公司 | Method for reducing content of galactosamine in heparin sodium through n-propyl alcohol extraction method |
| CN104140478B (en) * | 2013-05-08 | 2017-10-13 | 清华大学 | Fine work heparin and the method for preparing fine work heparin |
| CN103497262B (en) * | 2013-09-01 | 2016-05-04 | 黄伟 | A kind ofly extract the preparation method that heparin is received |
| CN103464222B (en) * | 2013-09-25 | 2015-11-18 | 凯瑞环保科技股份有限公司 | The preparation method of the special anion exchange resin of a kind of adsorbing liquaemin |
| CN103755836A (en) * | 2013-11-25 | 2014-04-30 | 青岛九龙生物医药有限公司 | Preparation technology for extracting heparin sodium crude product by utilizing animal lung |
| CN104017109B (en) * | 2014-06-20 | 2016-08-31 | 山东万邦赛诺康生化制药股份有限公司 | A kind of preparation method improving Enoxaparin Sodium clarity |
| CN105001353A (en) * | 2015-08-17 | 2015-10-28 | 江苏联众肠衣有限公司 | Refining optimization technology for crude heparin sodium |
| WO2018032502A1 (en) * | 2016-08-19 | 2018-02-22 | 苏州融析生物科技有限公司 | Sheep-derived low molecular weight heparin, preparation method therefor and application thereof |
| CN107759712B (en) * | 2016-08-19 | 2020-03-24 | 苏州融析生物科技有限公司 | Sheep-derived low-molecular-weight heparin and preparation method and application thereof |
| CN109438589B (en) * | 2018-11-19 | 2021-04-23 | 广东海洋大学 | Shellfish heparin with effect of relieving anticoagulation and preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0048231A1 (en) * | 1980-09-15 | 1982-03-24 | Kabi AB | Oligosaccharides having selective anticoagulation activity |
| US4518771A (en) * | 1979-03-21 | 1985-05-21 | Richter Gedeon Vegyeszeti Gyar Rt. | Process for the production of heparin-containing particulate products |
| CN1053361A (en) * | 1990-01-17 | 1991-07-31 | 大连生物化学制药厂 | Thromboembolism preventing blood fat reducing buccal tablet and production method thereof |
| US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
| EP0938507A1 (en) * | 1996-11-13 | 1999-09-01 | Günther Portenlänger | Process for preparing breakdown products of polymer glycosaminoglycans by means of ultrasound |
| CN1238182A (en) * | 1998-06-05 | 1999-12-15 | 何德惠 | Process for extracting coarse lipo-hepinette from lung of animal |
-
2000
- 2000-09-07 CN CN00125093A patent/CN1111171C/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518771A (en) * | 1979-03-21 | 1985-05-21 | Richter Gedeon Vegyeszeti Gyar Rt. | Process for the production of heparin-containing particulate products |
| EP0048231A1 (en) * | 1980-09-15 | 1982-03-24 | Kabi AB | Oligosaccharides having selective anticoagulation activity |
| CN1053361A (en) * | 1990-01-17 | 1991-07-31 | 大连生物化学制药厂 | Thromboembolism preventing blood fat reducing buccal tablet and production method thereof |
| US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
| EP0938507A1 (en) * | 1996-11-13 | 1999-09-01 | Günther Portenlänger | Process for preparing breakdown products of polymer glycosaminoglycans by means of ultrasound |
| CN1238182A (en) * | 1998-06-05 | 1999-12-15 | 何德惠 | Process for extracting coarse lipo-hepinette from lung of animal |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100344769C (en) * | 2005-08-04 | 2007-10-24 | 清华大学 | Production of low-molecular heparin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1283636A (en) | 2001-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1111171C (en) | Heparin and its preparing process | |
| KR101447123B1 (en) | Extraction Method of Heparin | |
| CN108329405B (en) | Method for protecting and purifying heparin sodium in resin adsorption state | |
| JP2002020402A (en) | Solid composition having selective bonding ability to dissolved iron | |
| US3451996A (en) | Method for the preparation of heparin | |
| CN1566162A (en) | Heparin sodium and its preparing process | |
| WO2008062998A1 (en) | Method for purifying hyaluronic acid | |
| CN106589167B (en) | The preparation method and its process units of high-titer crude heparin sodium | |
| CA1334516C (en) | Process for preparing high-purity dermatan sulphate, and pharmaceutical compositions which contain it | |
| CN102993298B (en) | Method for preparing alpha 1-antitrypsin | |
| CN1336434A (en) | Prepn. and affinity chromatographic purification process of kallidinogen enzyme | |
| CN106496363A (en) | A kind of efficient preparation technology of heparin sodium | |
| CN106519077A (en) | Preparation process of high-potency heparin sodium | |
| CN109467622A (en) | A method of extracting heparin sodium from intestinal mucosa | |
| CN103059129B (en) | Method for preparing human antithrombin-III product | |
| CN101348779B (en) | Method for extracting purified elastase from pig pancreas | |
| CN1308351C (en) | Exchange method of ionic equilibriom for heparin lithium | |
| CN113061199A (en) | Process for concentrating and extracting crude heparin sodium by using nanofiltration membrane | |
| CN112028988A (en) | Preparation method of freeze-dried human coagulation factor VIII | |
| KR100370929B1 (en) | Preparing Methode for Aqueous Chitosan | |
| CN104163878B (en) | A kind of method producing nadroparin calcium from heparin sodium crude | |
| CN110627848A (en) | Method for removing impurities in sialic acid and application thereof | |
| KR101780643B1 (en) | Method for purifying heparin using enzymolysis | |
| CN103724456A (en) | Technology for normal-temperature salt-free extraction of heparin sodium | |
| CN106866812B (en) | Method for extracting multiple urine proteins from urine of women |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |